标准化屋尘螨变应原特异性免疫治疗变应性鼻炎的疗效评估

发布时间：2018-03-09 23:23

本文选题：尘螨　切入点：特异性免疫治疗　出处：《临床耳鼻咽喉头颈外科杂志》2014年05期 　论文类型：期刊论文

【摘要】：目的:探讨标准化屋尘螨变应原特异性免疫治疗(SIT)变应性鼻炎(AR)的临床疗效。方法:将对屋尘螨过敏的102例AR患者随机分为2组,每组51例。SIT组:对症治疗基础上加用3年标准化屋尘螨变应原SIT;对症治疗组(ST组):仅对症治疗。评价疗效指标包括:鼻炎症状评分、用药评分、皮肤反应指数、血清特异性IgE(sIgE)、外周血嗜酸粒细胞(Eos)计数,AR发展成哮喘和出现新的致敏原的比例。结果:SIT组经3年治疗后,患者血清Eos计数、皮肤反应指数、症状及药物评分均较ST组明显降低(均P0.01);SIT后slgE有所下降,但差异无统计学意义。SIT组无AR患者发展为哮喘,2.1%出现新的致敏原;ST组17.4%的患者发展为哮喘,32.6%出现新的致敏原。治疗过程中未发生严重不良反应。结论:坚持长期SIT对螨致敏的AR安全有效,同时能减少新的过敏发生,阻止AR发展为哮喘。
[Abstract]:Objective: to investigate the clinical efficacy of standardized allergen specific immunotherapy for allergic rhinitis (ARA) of house dust mite. Methods: 102 patients with AR allergic to house dust mite were randomly divided into two groups. 51 cases in each group were treated with standardized house dust mite allergen sitt for 3 years on the basis of symptomatic treatment, and St group: symptomatic treatment only. Evaluation of curative effects included: rhinitis symptom score, medication score, skin reaction index, The ratio of AR to asthma and the occurrence of new allergens. Results after 3 years of treatment, the serum Eos count and skin reaction index of the patients in the group of 10% sit were compared. The symptom and drug score were significantly lower than those in St group (P 0.01) and the slgE was lower than that in St group (P 0.01). But there was no significant difference between the two groups. There was no significant difference between the two groups. In the SIT group, 2.1% of the patients developed asthma with a new allergen (St group 17.4%) and 32.6% of the patients in the St group developed a new allergen. There was no serious adverse reaction during the treatment. Conclusion: it is necessary to persist for a long period of time. SIT is safe and effective for mite sensitized AR. It also reduces the incidence of new allergies and prevents AR from developing into asthma.
【作者单位】：沈阳军区总医院全军呼吸内科及变态反应疾病诊治中心;
【分类号】：R765.21

【参考文献】